LFCR
Lifecore Biomedical, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$6.40
−1.84%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +9.2%
- EBITDA
- +72.1%
- EPS
- +12.3%
Three-year CAGR
- Revenue
- -35.7%
- EBITDA
- -43.6%
- EBIT
- +304.3%
- Net income
- +80.0%
- EPS
- +79.3%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2026